证券代码：603579 证券简称：荣泰健康 公告编号：2025-044 转债代码：113606 转债简称：荣泰转债 上海荣泰健康科技股份有限公司 关于公司可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （一）可转债发行情况 经中国证券监督管理委员会《关于核准上海荣泰健康科技股份有限公司公开 发行可转换公司债券的批复》（证监许可[2020]2139 号）核准，上海荣泰健康科 技股份有限公司（以下简称"公司"）于 2020 年 10 月 30 日公开发行了 600 万张 可转换公司债券，每张面值 100 元，发行总额 60,000.00 万元，期限 6 年，票面 利率：第一年 0.50%、第二年 0.70%、第三年 1.00%、第四年 1.50%、第五年 2.50%、 第六年 3.00%。 （二）可转债上市情况 经上海证券交易所《自律监管决定书》[2020]372 号文同意，公司 60,000.00 万元可转换公司债券于 2020 年 11 月 20 日起在上海证券交易所挂牌交易，债券 ...

Company Overview - The company is Shanghai Rongtai Health Technology Corporation Limited, primarily engaged in the design, research and development, production, and sales of massage equipment [11][12] - The company aims to provide a healthy and fashionable lifestyle to global users, focusing on shared massage services and experiences [11] Financial Performance - In the 2024 fiscal year, the company achieved a consolidated operating revenue of RMB 1,596.87 million, a decrease of 13.92% compared to the previous year [12][14] - The total profit for the year was RMB 209.99 million, down 8.77% year-on-year, while the net profit attributable to the parent company was RMB 163.21 million, a decline of 12.47% [12][14] - The company's total assets increased by 10.55% to RMB 3,742.04 million, and the net assets attributable to shareholders rose by 2.30% to RMB 2,014.12 million [14] Business Segmentation - The main business segments include manufacturing and service, with manufacturing accounting for RMB 1,569.96 million in revenue, down 14.64% year-on-year, and a gross margin of 31.44% [13] - The service segment generated RMB 4.99 million, with a gross margin of 68.47%, reflecting a decrease of 17.30% in revenue compared to the previous year [13] Product Performance - The primary products are massage chairs and small massage devices, with massage chairs generating RMB 1,031.44 million in revenue, a decrease of 14.05% year-on-year [15] - The gross margin for massage chairs was 32.06%, while small massage devices had a gross margin of 68.46%, showing an increase of 10.98 percentage points [15] Fundraising and Use of Proceeds - The company raised a total of RMB 600 million through the issuance of convertible bonds, with a net amount of RMB 593.98 million after expenses [12][14] - The funds are primarily allocated to the construction of a massage chair manufacturing base in Huzhou, Zhejiang [12][14] Debt and Credit Rating - The company’s convertible bonds have a credit rating of AA- with a stable outlook, as assessed by Shanghai New Century Credit Rating Co., Ltd [9] - The actual controller of the company, Lin Qi, has provided a guarantee for the bonds, covering 100% of the principal and interest [10]

股票代码：603579.SH 股票简称：荣泰健康 债券代码：113606.SH 债券简称：荣泰转债 上海荣泰健康科技股份有限公司 2020 年可转换公司债券 年度受托管理事务报告 （2024 年度） 债券受托管理人： （海口市南沙路 49 号通信广场二楼） 二〇二五年六月 重要声明 万和证券股份有限公司（以下简称"万和证券"）编制本报告的内容及信息来 源于上海荣泰健康科技股份有限公司（以下简称"荣泰健康"、"发行人"或"公司"） 对外公布的《上海荣泰健康科技股份有限公司 2024 年年度报告》等相关公开信 息披露文件、第三方中介机构出具的专业意见以及发行人向万和证券提供的资 料。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜做出独立判断，而不应将本报告中的任何内容据以作为万和证券所作的承诺 或声明。在任何情况下，投资者依据本报告所进行的任何作为或不作为，万和证 券不承担任何责任。 1 | | | 第一节 公司债券概要 一、发行人名称 中文名称：上海荣泰健康科技股份有限公司 英文名称：Shanghai Rongtai Health Technology Corporation Lim ...

Core Viewpoint - The brain-computer interface sector has seen a significant increase of 5.17%, ranking second among concept sectors, with 30 stocks rising, including notable gains from Xiangyu Medical and others [1][2]. Sector Performance - The brain-computer interface sector recorded a daily increase of 5.17%, with the top-performing stocks including Xiangyu Medical (20% limit up), Jihua Group, Innovation Medical, and Rongtai Health, all hitting the limit up [1][2]. - Other notable gainers in the sector included Aipeng Medical (10.82%), Mailande (8.71%), and Yingqu Technology (7.79%) [1]. Capital Flow - The brain-computer interface sector attracted a net inflow of 606 million yuan from main funds, with 19 stocks receiving net inflows, and 6 stocks exceeding 50 million yuan in net inflow [2]. - Innovation Medical led the sector with a net inflow of 312 million yuan, followed by Lepu Medical, Rongtai Health, and Hanwei Technology with net inflows of 99.42 million yuan, 74.91 million yuan, and 65.52 million yuan respectively [2][3]. Capital Inflow Ratios - Jihua Group and Rongtai Health had the highest net inflow ratios at 29.79% and 22.35% respectively, indicating strong investor interest [3]. - Other companies with notable inflow ratios included Junpu Intelligent (18.98%) and Innovation Medical (17.73%) [3].

Market Overview - The market experienced a rebound with the ChiNext Index leading the gains. The military industry sector saw significant growth, with over 20 stocks including Changcheng Military and Hunan Tianyan hitting the daily limit. The stablecoin concept also surged, with stocks like Hopu Co. and Xiexin Energy reaching their limits. Brain-computer interface stocks rose, with Xiangyu Medical and Innovation Medical hitting the limit. Overall, more than 4,000 stocks in Shanghai and Shenzhen markets were in the green, with a total transaction volume of 1.51 trillion [1]. Hot Topics Military Industry - The military sector continued its upward trend, with stocks like Changcheng Military, Feiyada, and Zhongguang Defense hitting consecutive limits. Hunan Tianyan and Beifang Navigation also saw significant rebounds [4]. RWA (Real World Assets) - The RWA sector experienced substantial gains, with stocks like Hopu Co. and Hangzhou Garden hitting their limits. The market is witnessing a rapid growth of RWA ecosystem participants, including issuers, custodial banks, and investors, which may present investment opportunities in asset operation, banking IT, and cross-border payments [6][8]. Brain Science - The brain science sector saw significant increases, with stocks like Rongtai Health and Innovation Medical hitting their limits. Recent developments from Neuralink, including clinical trials for brain-computer interfaces, have generated excitement in the market. The brain-computer interface market in China is projected to reach 3.2 billion by 2024 and exceed 5.5 billion by 2027, with global applications expected to reach between 40 billion to 145 billion by 2030-2040 [9][10][11].

Group 1 - The core viewpoint of the news is that Rongtai Health has invested in Shenzhen Hengqu Motor Co., Ltd., marking an extension into the upstream core components of the smart health industry chain [1] - This investment aims to enhance Rongtai Health's core competitiveness in the smart health sector by integrating cutting-edge technology to provide more efficient, greener, and smarter health product experiences for global users [1][2] - Hengqu Motor is recognized as a national-level specialized and innovative "little giant" enterprise, with over ten years of experience in the brushless motor field, offering 36 standard model series and over 500 customized drive solutions [1] Group 2 - The collaboration between Rongtai Health and Hengqu Motor will lead to advancements in several areas, including the upgrade of smart massage devices, where Hengqu's ultra-quiet brushless motor technology will significantly improve noise reduction during operation [2] - The partnership will also focus on innovation in health therapy robots, leveraging Hengqu's expertise in medical motor solutions to develop intelligent drive modules suitable for health therapy, thus expanding into emerging markets [2] - Additionally, the investment will enhance global supply chain collaboration, utilizing Hengqu's sales network across Europe, America, and Asia to strengthen Rongtai Health's localized supply capabilities in overseas markets [2]

Core Points - The company, Shanghai Rongtai Health Technology Co., Ltd., has maintained its credit rating of "AA-" for both its corporate and convertible bonds, with a stable outlook [1][2] - The tracking rating was conducted by Shanghai New Century Credit Rating Co., Ltd., based on a comprehensive analysis of the company's operational status and related industry [2] Group 1 - Previous bond rating was "AA-", with a stable outlook [1] - Current bond rating remains "AA-", with a stable outlook [2] - The tracking rating report was issued on June 23, 2025, and is available on the Shanghai Stock Exchange website [2]

| 证券代码：603579 | 证券简称：荣泰健康 | 公告编号：2025-043 | | --- | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | | 上海荣泰健康科技股份有限公司 关于可转换公司债券跟踪评级结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 根据中国证券监督管理委员会《公司债券发行与交易管理办法》、《上海证 券交易所股票上市规则》和《上市公司证券发行注册管理办法》的有关规定， 上海荣泰健康科技股份有限公司（以下简称"公司"）委托信用评级机构上海 新世纪资信评估投资服务有限公司（以下简称"上海新世纪"）对公司及 2021 年公开发行的可转换公司债券（以下简称"荣泰转债"）进行跟踪评级。 公司前次主体信用等级评级结果为"AA-"；前次"荣泰转债"信用等级评 级结果为"AA-"；评级机构为上海新世纪，评级时间为 2024 年 6 月 14 日。 上海新世纪在对公司经营状况及相关行业进行综合分析与评估的基础上， 于 2025 年 6 月 23 日出具了《上海 ...

内部编号:2025060183 上海荣泰健康科技股份有限公司 公开发行可转换公司债券 定期跟踪评级报告 | 项目负责人: | 黄梦姣 | 品,男女 | hm j@shxs j. com | | --- | --- | --- | --- | | 翁斯詰 | | 12557 85 | wsz@shxsj.com | | 项目组成员: | | | | | 评级总监: | 张明海 | 82-16 | | | 联系电话:(021)63501349 | | | | | 联系地址:上海市黄浦区汉口路 398 号华盛大厦 14 层 | | | | | 公司网站:www.shxsj.com | | | | 上海新世纪资信评估投资服务有限公司 Shanghai Brilliance Credit Rating & Investors Service Co. . Ltd. 声明 除因本次评级事项使本评级机构与评级对象构成委托关系外,本评级机构、评级人员与评级对象不存在任何影响 评级行为独立、客观、公正的关联关系。 本评级机构与评级人员履行了调查和诚信义务,所出具的评级报告遵循了真实、客观、公正的原则。 本报告的评级结论是本评级机 ...

| 证券代码：603579 | 证券简称：荣泰健康 | 公告编号：2025-042 | | --- | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | | 上海荣泰健康科技股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、公司关注并核实的相关情况 针对公司股票交易异常波动，公司对有关事项进行了核查，并书面征询了公 司控股股东及实际控制人，现将有关情况说明如下： 重要内容提示： 上海荣泰健康科技股份有限公司（以下简称"公司"）股票于 2025 年 6 月 17 日、2025 年 6 月 18 日、2025 年 6 月 19 日连续三个交易日内日收盘价格涨 幅偏离值累计超过 20%，根据《上海证券交易所交易规则》的有关规定，属于股 票交易异常波动。公司郑重提醒广大投资者注意交易风险，审慎决策，理性投资。 经公司自查并书面征询公司控股股东及实际控制人，截至本公告披露日， 除公司已披露事项外，不存在应披露而未披露的重大信息。 一、股票交易异常波动的具体情况 公司股票 ...